Your browser doesn't support javascript.
loading
A novel GTP-binding inhibitor, FX2149, attenuates LRRK2 toxicity in Parkinson's disease models.
Li, Tianxia; He, Xinhua; Thomas, Joseph M; Yang, Dejun; Zhong, Shijun; Xue, Fengtian; Smith, Wanli W.
  • Li T; Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, United States of America.
  • He X; Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, United States of America; Beijing Institute of Pharmacology and Toxicology, Beijing, China.
  • Thomas JM; Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, United States of America.
  • Yang D; Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, United States of America.
  • Zhong S; School of Life Science and Biotechnology, Dalian University of Technology, Liaoning, China.
  • Xue F; Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, United States of America.
  • Smith WW; Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, United States of America.
PLoS One ; 10(3): e0122461, 2015.
Article en En | MEDLINE | ID: mdl-25816252
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Proteínas Serina-Treonina Quinasas / Inhibidores Enzimáticos Límite: Animals / Humans Idioma: En Año: 2015 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Proteínas Serina-Treonina Quinasas / Inhibidores Enzimáticos Límite: Animals / Humans Idioma: En Año: 2015 Tipo del documento: Article